NCT05181865View on ClinicalTrials.gov

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

PHASE1/PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

January 31, 2022

Primary Completion Date

January 18, 2022

Study Completion Date

January 18, 2022

Conditions

Pancreas CancerGastric CancerSolid Tumor

Interventions

DRUG

1 mg/kg IV FL-301

N = 1

DRUG

3 mg/kg IV FL-301

N = 3-6

DRUG

10 mg/kg IV FL-301

N = 3-6

DRUG

20 mg/kg IV FL-301

N = 3-6

DRUG

30 mg/kg IV FL-301

N = 3-6

DRUG

RP2D, IV FL-301

Pancreatic Cancer N = 30

DRUG

RP2D, IV FL-301

Gastric Cancer (Including GEJ) N = 30

DRUG

RP2D, IV FL-301

Other Solid Tumors N = 30

Sponsors

Lead Sponsor

Flame Biosciences

All Listed Sponsors

lead

Flame Biosciences

INDUSTRY